Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rusal wants changes in Nornickel's top management

3/3/23 GMKN

Moscow Exchange summed up the results of trading in February

3/2/23 MOEX

Joint venture between the state and Rostelecom to develop the UBS is already in operation

3/2/23 RTKM

Big Lots' 2022 profits are up 18.5%

3/2/23 BIG

Macy's reported for 2022

3/2/23 M

Nornickel sells nickel to China for RMB at Shanghai Futures Exchange prices

3/2/23 GMKN

The Broadcom announced a quarterly dividend

3/2/23 AVGO

GAZ will start serial production of E-Citymax 18 electric coaches in 2023

3/2/23 GAZA

Global Ports will move to Russia by the end of this year

3/2/23 GLPR

En+ Group is studying the possibility of building a gas plant near the Kovykta field

3/2/23 ENPG